HUMANA INC: directors' dealings · United States · SEC (Form 4)

About HUMANA INC

Humana Inc. (ticker: HUM) is a major U.S. healthcare company listed on the NYSE in the United States. The group has long been associated with health insurance and has evolved into a more integrated health and well-being platform, with a strong focus on seniors and government-sponsored programs. Founded in 1961, Humana built its franchise around medical coverage and later expanded into care coordination, clinical services, and member support. Its headquarters are in Louisville, Kentucky, and the company operates through a large network of associates and care partners across the country. ([sec.gov](https://www.sec.gov/Archives/edgar/data/49071/000110465926024400/tm266867d2_ars.pdf)) Humana’s business model is centered on Medicare Advantage plans, medical benefit administration, Medicare Part D offerings, and complementary specialty products, alongside the continued expansion of CenterWell, its care delivery and pharmacy services platform. The company also emphasizes value-based care, a strategic pillar designed to improve clinical outcomes while supporting cost discipline. In 2025, Humana reported approximately 15.0 million medical members and 4.7 million specialty members, underscoring its scale in the U.S. health insurance market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000049071/000110465926024400/tm266867d2_ars.pdf)) From a competitive standpoint, Humana remains one of the leading managed-care players in the United States, with particularly strong visibility in Medicare Advantage. Its positioning is supported by an established brand, a growing clinical footprint, and a strategy aimed at simplifying the member experience. Management has repeatedly framed the company’s mission around making the U.S. healthcare system easier to navigate and more intuitive for consumers. That approach differentiates Humana from peers that may focus more narrowly on insurance underwriting alone. ([sec.gov](https://www.sec.gov/Archives/edgar/data/49071/000110465926024400/tm266867d2_ars.pdf)) Recent developments suggest a phase of strategic recalibration rather than a simple growth-at-all-costs approach. In its first-quarter 2026 results, Humana reaffirmed full-year adjusted guidance and said it expects individual Medicare Advantage membership to grow by approximately 25% in 2026 versus 2025, driven by new sales and improved retention. The company has also continued to invest in value-based care and health-data interoperability, including new clinical partnerships and digital initiatives intended to make access to health information easier for members. For French-speaking investors, HUM is therefore best viewed as a NYSE-listed U.S. healthcare leader with meaningful regulatory exposure, but also with a clear operating lever in integrated Medicare-focused services. ([policy.humana.com](https://policy.humana.com/news-and-resources/news-press/2026/humana-reports-first-quarter-2026-financial-results--affirms-ful?utm_source=openai))